{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:27:34Z","timestamp":1790774854722,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.amjcard.2020.12.020","type":"journal-article","created":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T22:46:46Z","timestamp":1615243606000},"page":"S23-S31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"S1","title":["Dual Antiplatelet Therapy De-escalation Strategies"],"prefix":"10.1016","volume":"144","author":[{"given":"Peter R","family":"Sinnaeve","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Adriaenssens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2020.12.020_bib0001","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0002","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease","volume":"68","author":"Levine","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0003","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/j.jacc.2013.08.1625","article-title":"The clinical outcomes of percutaneous coronary intervention performed without pre-procedural aspirin","volume":"62","author":"Kenaan","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0004","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.jacc.2008.04.002","volume":"51","author":"Antman","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0005","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1093\/eurheartj\/ehr422","article-title":"Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"32","author":"Becker","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0006","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/eurheartj\/ehx175","article-title":"Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study","volume":"38","author":"Cuisset","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0007","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","article-title":"Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial","volume":"390","author":"Sibbing","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0008","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","article-title":"Ten berg JM. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI","volume":"381","author":"Claassens","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0009","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.2020.12443","article-title":"Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial","volume":"324","author":"Pereira","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0010","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4244\/EIJY14M06_09","volume":"11","author":"Onuma","year":"2015","journal-title":"EuroIntervention"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0011","doi-asserted-by":"crossref","first-page":"k3793","DOI":"10.1136\/bmj.k3793","article-title":"Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial","volume":"363","author":"Kedhi","year":"2018","journal-title":"Bmj"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0012","doi-asserted-by":"crossref","first-page":"e990","DOI":"10.4244\/EIJ-D-19-00539","article-title":"Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial)","volume":"15","author":"De Luca","year":"2019","journal-title":"EuroIntervention"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0013","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(18)30493-8","article-title":"6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial","volume":"391","author":"Hahn","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0014","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","article-title":"Polymer-free Drug-Coated coronary stents in patients at high bleeding risk","volume":"373","author":"Urban","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0015","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(17)32713-7","article-title":"Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial","volume":"391","author":"Varenne","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0016","first-page":"189","article-title":"Rewinder Study G. Real world insights on the initiation and treatment duration of oral antiplatelets in acute coronary syndromes: a retrospective cohort study","volume":"3","author":"Claeys","year":"2017","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0017","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10557-020-06963-5","article-title":"Real-world dual antiplatelet therapy following polymer-free sirolimus-eluting stent implantations to treat coronary artery disease","volume":"34","author":"Krackhardt","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0018","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/jth.13216","article-title":"Effects of P2Y12 receptor inhibition with or without aspirin on hemostatic system activation: a randomized trial in healthy subjects","volume":"14","author":"Traby","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0019","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1538-7836.2010.04160.x","article-title":"In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation","volume":"9","author":"Armstrong","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0020","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jacc.2019.11.056","article-title":"Ticagrelor with or without aspirin after pci: the TWILIGHT platelet substudy","volume":"75","author":"Baber","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0021","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/hrt.2010.205724","article-title":"Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists?","volume":"96","author":"Warner","year":"2010","journal-title":"Heart"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0022","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0023","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0024","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0025","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0026","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/j.jacc.2019.08.1038","article-title":"Ticagrelor alone versus dual antiplatelet therapy from 1 month after drug-eluting coronary stenting","volume":"74","author":"Franzone","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0027","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0028","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1161\/CIRCULATIONAHA.120.046251","article-title":"The safety and efficacy of aspirin discontinuation on a background of a P2Y(12) inhibitor in patients after percutaneous coronary intervention: a systematic review and meta-analysis","volume":"142","author":"O'Donoghue","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0029","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.jcin.2018.12.005","article-title":"Validation of high-risk features for stent-related ischemic events as endorsed by the 2017 DAPT guidelines","volume":"12","author":"Ueki","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0030","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jacc.2018.11.048","article-title":"Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting","volume":"73","author":"Costa","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0031","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1093\/eurheartj\/ehz453","article-title":"Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial","volume":"40","author":"Serruys","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0032","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2019.3355","article-title":"Benefit and risks of aspirin in addition to ticagrelor in acute coronary syndromes: a post hoc analysis of the randomized GLOBAL LEADERS trial","author":"Tomaniak","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0033","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/j.jacc.2019.08.997","article-title":"Efficacy and safety of ticagrelor monotherapy in patients undergoing multivessel PCI","volume":"74","author":"Takahashi","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0034","first-page":"100","article-title":"Clinical relevance of ticagrelor monotherapy following 1-month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: insight from GLOBAL LEADERS trial","volume":"96","author":"Kogame","year":"2020","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0035","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1016\/j.jacc.2020.03.011","article-title":"Ticagrelor with or without aspirin after complex PCI","volume":"75","author":"Dangas","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0036","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1016\/j.jacc.2020.03.008","article-title":"Ticagrelor with or without aspirin in high-risk patients with diabetes mellitus undergoing percutaneous coronary intervention","volume":"75","author":"Angiolillo","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0037","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaa624","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","author":"Collet","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0038","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1161\/CIRCULATIONAHA.120.046534","article-title":"Risk\/benefit tradeoff of antithrombotic therapy in patients with atrial fibrillation early and late after an acute coronary syndrome or percutaneous coronary intervention: insights from AUGUSTUS","volume":"141","author":"Alexander","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2020.12.020_bib0039","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/09537104.2019.1572880","article-title":"Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome","volume":"30","author":"Parker","year":"2019","journal-title":"Platelets"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914920313473?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914920313473?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:37:03Z","timestamp":1757572623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914920313473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":39,"alternative-id":["S0002914920313473"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2020.12.020","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual Antiplatelet Therapy De-escalation Strategies","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2020.12.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}